Shanxi C&Y Pharmaceutical Group Co Ltd
Shanxi C&Y Pharmaceutical Group Co Ltd is a pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products.
Business. Shanxi C&Y Pharmaceutical Group Co Ltd (300254.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shanxi C&Y Pharmaceutical Group Co Ltd (300254.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Shanxi C&Y Pharmaceutical Group Co Ltd has a debt-to-equity ratio of 2.31, indicating a capital structure that is heavily leveraged relative to equity. The company's liquidity is assessed as medium, with a current ratio of 0.98, suggesting that it has nearly equal current assets and liabilities. Free cash flow stands at 57.42 million CNY, which is a positive sign for operational flexibility, though the company's net cash position is negative after subtracting total debt.
Profitability metrics show a return on equity (ROE) of 8.16% and a return on assets (ROA) of 1.51%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, which often sees ROE above 10% and ROA above 5%. The company's net income of 24.85 million CNY is relatively modest compared to its revenue of 870.79 million CNY, indicating a net margin of approximately 2.85%.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks if demand for its products fluctuates in its primary market.
Looking ahead, the company's revenue is projected to grow by a modest amount in the current fiscal year, though the exact numeric delta is not disclosed. The capital expenditure of -34.32 million CNY suggests that the company is not investing heavily in new projects or infrastructure, which may limit its long-term growth potential.
The company faces several risk factors, including its high debt load and the potential for dilution. The risk assessment indicates a low probability of dilution in the near term, but the presence of a negative net cash position raises concerns about liquidity risk. The company's debt-to-equity ratio of 2.31 is significantly higher than the industry median, which may increase its vulnerability to interest rate fluctuations and economic downturns.
Recent events, including filings and transcripts, have not revealed any major strategic shifts or new product launches. The company's financial statements and disclosures suggest a stable but conservative approach to capital allocation and growth.
- The company has a high debt-to-equity ratio of 2.31, indicating a capital structure that is heavily leveraged.
- Return on equity of 8.16% and return on assets of 1.51% are below typical industry benchmarks.
- Free cash flow of 57.42 million CNY provides some operational flexibility, but the company's net cash position is negative after subtracting total debt.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company is not investing heavily in new projects or infrastructure, as indicated by a capital expenditure of -34.32 million CNY.
- The risk assessment indicates a low probability of dilution in the near term, but liquidity risk remains a concern.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Shanxi C&Y Pharmaceutical Group Co Ltd Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Qun ZhaoPresident, Director